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Abstract
Multiple myeloma presenting as an intracranial tumor (plasmacytoma) is very rare. An 81-year-old
woman was admitted to our hospital because of gait disturbance. A blood laboratory test revealed
a mildly increased lactate dehydrogenase (236 IU/L) and glucose (121 mg/dl). Blood protein
fractions were normal. Brain computed tomography and magnetic resonance imaging revealed an
intracranial mass (5 × 4 × 3 cm) in the brain base next to the clavus, and it was clinically diagnosed
as chordoma. An excision of the brain tumor was performed. Imaging modalities including
ultrasound, x-ray, computed tomography, magnetic resonance imaging and positron emission
tomography did not reveal any tumors other than the brain tumor. The tumor was soft, fragile, and
bloody. Microscopically, a monotonous proliferation of atypical plasma cells with hyperchromatic
nuclei was recognized. Histochemically, the tumor cells were pyroninophilic and the congo-red
stain revealed amyloidosis. Immunohistochemically, the tumor cells were positive for κ-chain and
negative for cytokeratin, epithelial membrane antigen, vimentin, CD45, CD20, CD45RO, λ-chain,
IgM, IgA, IgG, synaptophysin, chromogranin, S100 protein, desmin, α-smooth muscle antigen,
myoglobin, p53 protein, and glial fibrillary acidic protein. The Ki-67 labeling was 11%. Intracranial
plasmacytoma was pathologically diagnosed. The patient was treated by adjuvant chemoradiation,
and entered into the complete remission stage. However, multiple metastases emerged in the
vertebral bones and ribs six months after the remission. A diagnosis of multiple myeloma was made.
The urine revealed Bence-Jones protein of monoclonal IgG κ-chain type, but blood M protein was
not recognized. The patient's condition gradually deteriorated. The patient died of respiratory
failure due to bronchopneumonia 18 months after the admission. The present case indicates that
multiple myeloma may manifest as an intracranial brain tumor (plasmacytoma).
Introduction
Multiple myeloma (MM) is a serous malignant neoplasm
of bone marrow, and mostly occurs in the elderly persons.
The tumor cells of this disease are plasma cells, and pro-
duce immunoglobulins and/or light chains. It is occasion-
ally complicated by amyloidosis. MM is usually detected
in bones with characteristic features of punched-out
lesions. MM presenting as an intracranial brain tumor or
intracranial plasmacytoma is very rare; a survey of the
world literature revealed only 7 such cases [1-7]. Here, the
author reports an intracranial brain tumor of plasmacy-
toma, which later developed into MM.
Case presentation
An 81-year-old woman complained of gait disturbance,
and consulted to our hospital for scrutiny. A blood labo-
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ratory test revealed a mildly elevated LDH (236 IU/L) and
glucose (121 mg/dl). Blood protein fractions were nor-
mal, and no hyper-λ-globurinemia and M-protein were
recognized. Brain X-P, CT and MRI revealed an intracra-
nial mass (5 × 4 × 3 cm) in the brain base next to the cla-
vus (Figure 1), and it was clinically diagnosed as
chordoma by radiologists and neurosurgeons. An excision
of the brain tumor was performed. Imaging modalities
including US, X-P, CT, MRI and PET revealed no tumors
in the extracranial locations.
Grossly, the brain tumor was soft, fragile, and bloody dur-
ing the operation. Microscopically, a monotonous prolif-
eration of atypical plasma cells with hyperchromatic
nuclei was recognized (Figures 2 and 3). Histochemically,
the tumor cells were pyroninophilic (Figure 4) and the
congo-red stain revealed amyloidosis (Figure 5).
An immunohistochemical study was performed with the
use of Dako Envision method (Dako, Glostrup, Den-
mark), as described previously [8,9]. The antibodies used
were as follows: pancytokeratin (AE 1/3, Dako), pancy-
tokeratin (CAM5.2, Beckton-Dickinson, CA, USA), epi-
thelial membrane antigen (E29, Dako), CD45 (LCA,
Dako), CD20 (L26, Dako), CD45RO (UCHL-1, Dako), κ-
chain (polyclonal, Dako), λ-chain (polyclonal, Dako),
IgG (polyclonal, Dako), IgM (polyclonal, Dako), IgA
(polyclonal, Dako), CD68 (KP-1, Dako), synaptophysin
(polyclonal Dako), chromogranin (DAK-A3, Dako), S100
protein (polyclonal, Dako), desmin (D33, Dako), α-
smooth muscle antigen (1A4, Dako), myoglobin (poly-
clonal. Dako), p53 protein (DO7, Dako), Ki-67 antigen
(MIB-I, Dako), and glial fibrillary acidic protein (GFAP)
(6F2, Dako).
The tumor cells were positive for κ-chain (Figure 6). How-
ever, they were negative for cytokeratin, epithelial mem-
brane antigen, vimentin, CD45, CD20, CD45RO, λ-chain,
IgM, IgA, IgG, synaptophysin, chromogranin, S100 pro-
tein, desmin, α-smooth muscle antigen, myoglobin, p53
MRI findings Figure 1
MRI findings. An intracranial tumor is present in the brain 
base next to the clavus.
Low power microscopic view Figure 2
Low power microscopic view. Proliferation of small atyp-
ical cells is seen. HE, ×10.
Higher power microscopic view Figure 3
Higher power microscopic view. The tumor cells are 
round cells with eccentrically located nuclei. The nuclei show 
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protein, and GFAP. The Ki-67 labeling was 11% (Figure
7).
Intracranial plasmacytoma was pathologically diagnosed.
The patient was treated by adjuvant chemoradiation, and
entered into the complete remission stage. However, mul-
tiple metastases emerged in the vertebral bones and ribs
six months after the remission. A diagnosis of MM was
made. The urine revealed Bence-Jones protein of mono-
clonal IgG κ-chain type, but blood M protein was not rec-
ognized. The patient's condition gradually deteriorated.
The patient died of respiratory failure due to bronchop-
neumonia 18 months after the admission. Autopsy was
not performed.
Discussion
MM or plasmacytoma presenting as an intracranial brain
tumor is extremely rare. A review of the world literature
revealed only 7 such cases. In the present case, the intrac-
ranial brain tumor was first diagnosed as chordoma, and
signs and symptoms of MM including bone pain and
blood M-protein were not recognized. The pathological
examination, for the first time, revealed that the brain
tumor was a plasmacytoma.
The pathologic diagnosis was apparently correct. Since,
the plasma cells showed cellular atypia, the plasmacy-
toma was malignant. The pyroninophilia of tumor cells
and the presence of amyloidosis strongly support the
The tumor cells are pyroninophilic Figure 4
The tumor cells are pyroninophilic. Methylgreen pyro-
nine, ×400.
Amyloid is scattered Figure 5
Amyloid is scattered. Congo-red stain, ×200.
The tumor cells are positive for κ light chain Figure 6
The tumor cells are positive for κ light chain. Immu-
nostaining, ×400.
The Ki-67 labeling is 11% Figure 7
The Ki-67 labeling is 11%. Immunostaining, ×100.Publish with BioMed Central    and   every 
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pathologic diagnosis of plasmacytoma. Further, the
tumor cells were positive for κ-chain and negative for λ-
chain, strongly suggesting the monoclonal proliferation
of the tumor plasma cells. Curiously, the immunohisto-
chemical study was negative for IgG, IgM, and IgA. Later,
the urine test showed Bence-Jones protein with mono-
clonal IgG κ-chain. This may suggest that at first the tumor
cells produced only κ light chain.
It is not certain whether the brain tumor was the manifes-
tation of MM or the brain tumor of plasmacytoma gradu-
ally transformed into MM. Clinical course indicated that
at first only the intracranial brain tumor was detected.
After the adjuvant chemoradiation therapy, complete
remission was obtained. The multiple bone lesions were
detected six months after the operation and adjuvant
chemoradiation therapy. These features may suggest that
the intracranial plasmacytoma evolved into MM. How-
ever, there is a possibility that the intracranial brain tumor
is the first manifestation of MM.
In summary, the present case indicates that MM may be
preceded by or manifested as an intracranial brain tumor
(plasmacytoma).
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